Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

TRIM33 (Tripartite Motif Containing 33)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

Tempus xO assay

Tempus xO assay

›

SEPTIN6-TRIM33 fusion	Diffuse Large B Cell Lymphoma	SEPTIN6-TRIM33 fusion	Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials R-CHOP Sensitive : C3	R-CHOP Sensitive: C3 – Early Trials R-CHOP Sensitive : C3
SEPTIN6-TRIM33 fusion	Diffuse Large B Cell Lymphoma	SEPTIN6-TRIM33 fusion	Diffuse Large B Cell Lymphoma	R-CEOP Sensitive: C3 – Early Trials R-CEOP Sensitive : C3	R-CEOP Sensitive: C3 – Early Trials R-CEOP Sensitive : C3
ID2 overexpression + TRIM33 overexpression	Squamous Cell Carcinoma of Head and Neck	ID2 overexpression + TRIM33 overexpression	Squamous Cell Carcinoma of Head and Neck	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3
ID2 overexpression + TRIM33 overexpression	Squamous Cell Carcinoma of Head and Neck	ID2 overexpression + TRIM33 overexpression	Squamous Cell Carcinoma of Head and Neck	paclitaxel Sensitive: C3 – Early Trials paclitaxel Sensitive : C3	paclitaxel Sensitive: C3 – Early Trials paclitaxel Sensitive : C3
ID2 overexpression + TRIM33 overexpression	Squamous Cell Carcinoma of Head and Neck	ID2 overexpression + TRIM33 overexpression	Squamous Cell Carcinoma of Head and Neck	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
TRIM33-RET fusion + EGFR mutation	Lung Cancer	TRIM33-RET fusion + EGFR mutation	Lung Cancer	EGFR inhibitor Resistant: C4 – Case Studies EGFR inhibitor Resistant : C4	EGFR inhibitor Resistant: C4 – Case Studies EGFR inhibitor Resistant : C4
TRIM33-RET fusion	Sarcoma	TRIM33-RET fusion	Sarcoma	selpercatinib Sensitive: C4 – Case Studies selpercatinib Sensitive : C4	selpercatinib Sensitive: C4 – Case Studies selpercatinib Sensitive : C4
TRIM33-BRAF fusion	Melanoma	TRIM33-BRAF fusion	Melanoma	tovorafenib Sensitive: C4 – Case Studies tovorafenib Sensitive : C4	tovorafenib Sensitive: C4 – Case Studies tovorafenib Sensitive : C4
TRIM33-RET fusion	Lung Adenocarcinoma	TRIM33-RET fusion	Lung Adenocarcinoma	cabozantinib tablet Sensitive: D – Preclinical cabozantinib tablet Sensitive : D	cabozantinib tablet Sensitive: D – Preclinical cabozantinib tablet Sensitive : D
TRIM33-RET fusion	Non Small Cell Lung Cancer	TRIM33-RET fusion	Non Small Cell Lung Cancer	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D
RET-TRIM33 fusion	Lung Cancer	RET-TRIM33 fusion	Lung Cancer	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D